Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TmPSMA-02 in mCRPC
NCT05489991Phase 2Terminated
- Sponsor
- Tceleron Therapeutics, Inc.
- Start
- Sep 2022
- Primary completion
- May 2023
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of TmPSMA-02 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Tceleron Therapeutics, Inc.. Started Sep 2022; status: terminated.
02
Drugs
TmPSMA-02
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05489991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05489991.